A breast cancer study treats its first patient by freezing a tumor

IceCure Medical (ICCM) treated the first patient in its ChoICE Study at West Cancer Center, using its ProSense® cryoablation system for breast cancer. The study aims to enroll 400 patients across 30 U.S. sites, generating real-world data. ProSense® is FDA-cleared for specific breast cancer treatments. IceCure develops cryoablation therapy systems for tumor destruction.

Original reporting
Published Oct 27, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ICCM
Bullish
high confidence
Mentioned
$ICCM
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ICCMBullishMed
01

Why it matters

The trial start provides a tangible milestone that can be used to gauge future commercial traction and revenue potential.

02

Market read

First‑patient enrollment signals progress toward commercial rollout, which may attract biotech investors seeking early‑stage device breakthroughs.

03

What to watch

Regulatory timelines, reimbursement landscape, and competition from alternative ablation technologies.

Relevance 8/10Novelty 8/10Timing: today

Background

Icecure Medical develops liquid‑nitrogen cryoablation systems; the ProSense® device is FDA‑cleared for low‑risk breast cancer in patients 70+.

Company-level read

Ticker impact

$ICCMBullishHigh confidence
Context

Icecure Medical announced the first patient was treated in its ChoICE Study, marking the start of patient enrollment for its ProSense® breast cancer cryoablation system.

Expected impact

likely upward pressure as investors price in future data and potential market expansion

Evidence & confidence

Trial initiation is a material milestone for a biotech device company; positive perception can lift the stock ahead of forthcoming data.

Market effects

May boost interest in minimally invasive oncology devices and cryoablation technologies.

Primarily U.S. biotech and medical device markets.

Limited to investors tracking early-stage medical device pipelines.

Counterpoint

If early data are inconclusive, the stock could face disappointment and sell‑off.

Key entities

  • Icecure Medical

    NASDAQ‑listed developer of cryoablation devices.

  • West Cancer Center & Research Institute

    Clinical site where the first patient was treated.

Related articles

$ICCMMed

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) announced the successful treatment of the first patient in its ChoICE post-marketing study for breast cancer cryoablation. The study, led by West Cancer Center in Tennessee, aims to enroll 400 patients across 30 U.S. sites. The company's ProSense® system is FDA-cleared for specific breast cancer treatments. IceCure expects the study to support broader adoption of its cryoablation technology.

$ICCMHighAI 8/10

IceCure Medical Wins Regulatory Approval To Market ProSense In China

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

$ICCMMed

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

IceCure Medical (ICCM) received IRB approval from West Cancer Center for its ChoICE study on ProSense® cryoablation for low-risk breast cancer. The study, expected to enroll patients soon, aims to gather real-world data on the treatment. ProSense® is FDA-approved for women 70+ with low-risk tumors. The study will involve 30 sites and 400 patients, expanding access to cryoablation.

$ICCMMed

IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript

IceCure Medical (ICCM) reported $1.8M in H1 2026 revenue, up 45% YoY. U.S. revenue grew 64% post-FDA clearance. Gross profit rose 57% to $548K, but net loss widened to $8.8M. Cash increased to $12M after $8.5M Q2 financing. Management highlighted growth in system and disposable probe sales, U.S. expansion, and the CHOICE study.